Avanir's stock price fell fairly sharply from the peak hit right after Neudexta's approval last October but the stock has started to come back lately as the launch date nears.
Pat. W. asks, "Adam, I have been following Discovery Labs (DSCO) for many years and I thinking it's time to invest in Surfaxin getting a favorable review. My concern is buying before a possible reverse stock split and/or continued dilution of the stock, but I like your optimistic view of Surfaxin. What price per share range would you give Discovery if Surfaxin gets approval? Thanks."
I was feeling more snarky than usual Thursday morning, so in response to Discovery's announcement of yet another conference call scheduled to explain the 4,672nd delay in the Surfaxin resubmission process, I tweeted this:
"Memo to $DSCO CEO Tom Amick: STFU! No conf calls. No PRs. Not until you get Surfaxin approved. No one cares until then -- 2015? 2020?"And I mean it. Amick really need to shut his mouth and just get the job done. Enough explanations, enough excuses. Talk to investors after Surfaxin is approved. Until then, his words are useless. As for investing in Discovery, haven't you been hurt enough already? Revisit the stock when Surfaxin is approved, if ever. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV